» Articles » PMID: 35924947

Human Microbiota Colonization and Pancreatic Ductal Carcinoma

Overview
Publisher Informa Healthcare
Specialty Microbiology
Date 2022 Aug 4
PMID 35924947
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a high mortality rate and a poor prognosis. The human microbiota has been confirmed to participate in oncogenesis and may influence the treatment response to both chemotherapy and immunotherapy. Evidence for the association of the microbiota with PDAC risk, tumorigenesis, treatment response, and survival period is rapidly emerging. The oral microbiota and gut microbiota have the potential to be used in early diagnosis and risk stratification. Intratumor microbiota-targeted intervention strategies may be used as adjuvants to current treatments to improve therapeutic efficacy and overall survival. Here, we summarize the effect and association of the oral, gut and intratumor microbiota on the oncogenesis, progression and treatment of PDAC, as well as the potential of the microbiota to serve as a biomarker for the diagnosis and prognosis of PDAC, as well as a therapeutic target.

Citing Articles

Dysbiosis-NK Cell Crosstalk in Pancreatic Cancer: Toward a Unified Biomarker Signature for Improved Clinical Outcomes.

Fanijavadi S, Jensen L Int J Mol Sci. 2025; 26(2).

PMID: 39859442 PMC: 11765696. DOI: 10.3390/ijms26020730.


Intratumor microbiota and colorectal cancer: Comprehensive and lucid review.

Zong Z, Zeng W, Li Y, Wang M, Cao Y, Cheng X Chin J Cancer Res. 2025; 36(6):683-699.

PMID: 39802896 PMC: 11724182. DOI: 10.21147/j.issn.1000-9604.2024.06.07.


Oral microbiome-driven virulence factors: A novel approach to pancreatic cancer diagnosis.

Zeng X, Ren D, Liu R, Zhang Q, Yan X, Yuan X Biomol Biomed. 2023; 24(4):952-958.

PMID: 38153528 PMC: 11293218. DOI: 10.17305/bb.2023.9934.


The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer.

Rogers S, Charles A, Thomas R Cancers (Basel). 2023; 15(24).

PMID: 38136254 PMC: 10741649. DOI: 10.3390/cancers15245708.